EP1003778A1 - Isolated osteocalcin fragments - Google Patents
Isolated osteocalcin fragmentsInfo
- Publication number
- EP1003778A1 EP1003778A1 EP98929457A EP98929457A EP1003778A1 EP 1003778 A1 EP1003778 A1 EP 1003778A1 EP 98929457 A EP98929457 A EP 98929457A EP 98929457 A EP98929457 A EP 98929457A EP 1003778 A1 EP1003778 A1 EP 1003778A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fragment
- amino acid
- hoc
- osteocalcin
- carboxylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 86
- 102000004067 Osteocalcin Human genes 0.000 title claims abstract description 45
- 108090000573 Osteocalcin Proteins 0.000 title claims abstract description 45
- 210000002700 urine Anatomy 0.000 claims abstract description 71
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 29
- 238000003018 immunoassay Methods 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 13
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 13
- 238000005259 measurement Methods 0.000 claims abstract description 13
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 12
- 239000004220 glutamic acid Substances 0.000 claims abstract description 12
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 7
- 230000008416 bone turnover Effects 0.000 claims abstract description 6
- 238000011835 investigation Methods 0.000 claims abstract description 6
- 208000029725 Metabolic bone disease Diseases 0.000 claims abstract description 5
- 150000002307 glutamic acids Chemical class 0.000 claims abstract 6
- 235000001014 amino acid Nutrition 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 230000036963 noncompetitive effect Effects 0.000 claims description 6
- 238000002967 competitive immunoassay Methods 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 101001086210 Homo sapiens Osteocalcin Proteins 0.000 description 132
- 102000055149 human BGLAP Human genes 0.000 description 132
- 238000003556 assay Methods 0.000 description 77
- 210000002966 serum Anatomy 0.000 description 40
- 210000000988 bone and bone Anatomy 0.000 description 21
- 101000586335 Bos taurus Osteocalcin Proteins 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000002294 pubertal effect Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 125000000291 glutamic acid group Chemical class N[C@@H](CCC(O)=O)C(=O)* 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000006251 gamma-carboxylation Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 244000118350 Andrographis paniculata Species 0.000 description 5
- 102000005572 Cathepsin A Human genes 0.000 description 5
- 108010059081 Cathepsin A Proteins 0.000 description 5
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 229910052693 Europium Inorganic materials 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 230000004097 bone metabolism Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000013522 chelant Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000012875 competitive assay Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010074860 Factor Xa Proteins 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229960003330 pentetic acid Drugs 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000123 anti-resoprtive effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 101150035627 hoc gene Proteins 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229960001407 sodium bicarbonate Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- SLEWGAUJQCRZIF-UHFFFAOYSA-N 2-[[6-[[bis(carboxymethyl)amino]methyl]-4-[2-(4-isothiocyanatophenyl)ethynyl]pyridin-2-yl]methyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CC1=NC(CN(CC(O)=O)CC(=O)O)=CC(C#CC=2C=CC(=CC=2)N=C=S)=C1 SLEWGAUJQCRZIF-UHFFFAOYSA-N 0.000 description 1
- WDIAWYLBZSCZHW-UFLZEWODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid;isothiocyanic acid Chemical compound N=C=S.N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 WDIAWYLBZSCZHW-UFLZEWODSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000018083 Bone metabolism disease Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 108010072454 CTGCAG-specific type II deoxyribonucleases Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- SCCPDJAQCXWPTF-VKHMYHEASA-N Gly-Asp Chemical compound NCC(=O)N[C@H](C(O)=O)CC(O)=O SCCPDJAQCXWPTF-VKHMYHEASA-N 0.000 description 1
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 description 1
- 241001622557 Hesperia Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
- 241000539428 Hybroma Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- LNBHUCHAFZUEGJ-UHFFFAOYSA-N europium(3+) Chemical compound [Eu+3] LNBHUCHAFZUEGJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- DVCSNHXRZUVYAM-BQBZGAKWSA-N leu-asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O DVCSNHXRZUVYAM-BQBZGAKWSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 125000003259 prostaglandin group Chemical group 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000013214 routine measurement Methods 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- QQWYQAQQADNEIC-RVDMUPIBSA-N tert-butyl [(z)-[cyano(phenyl)methylidene]amino] carbonate Chemical compound CC(C)(C)OC(=O)O\N=C(/C#N)C1=CC=CC=C1 QQWYQAQQADNEIC-RVDMUPIBSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001685 time-resolved fluorescence spectroscopy Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Definitions
- This invention relates to an isolated osteocalcin fragment derived from human urine, a monoclonal antibody or recombinant antibody fragment capable to bind said fragment, a cell line producing said monoclonal antibody, and an immunoassay for quantitative determination of said fragment. Furthermore, the invention concerns a method for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders.
- hOC Human osteocalcin
- BGP bone Gla protein
- Peptide bonds between arginine residues 19 and 20 and between residues 43 and 44 are susceptible to tryptic hydrolysis leading to peptides 1-19, 20- 43, 45-49, 1-43, and 20-49 which may be the main products of hOC breakdown in the circulation (Farrugia and Melick, Calcif Tissue Int 1986; 39:234-8, Hellman et al. J Bone Miner Res 1996; 11 : 1 165-75 and Garnero et al. J Bone Miner Res 1994; 9:255-4).
- Multiple immunoreactive forms of hOC have been discovered in circulation (Garaero et al. J Bone Miner Res 1994; 9:255-4) and also in urine (Taylor et al.
- the fragments of hOC can be produced either during osteoclastic degradation of bone matrix or as the result of the catabolic breakdown of the circulating protein after synthesis by osteoblasts. There is evidence that the production of some of the fragments found in urine occurs before renal clearance and is not a result of it (Taylor et al. J Clin Endocrin Metab. 1990; 70:467-72). Because of the rapid clearance from the circulation by glomerular filtration, the shOC (serum human OC) could reflect the acute changes in bone metabolism, while some of the uhOC (urine human OC) fragments might serve as an index of long term changes (Price et al. J Biol Chem 1980; 256: 12760-6).
- the first reported measurement of urine osteocalcin (Taylor et al. J Clin Endocrin Metab. 1990; 70:467 - 72) is based on competitive RIA utilizing polyclonal guinea pig antihuman OC antibodies for recognizing the immunoreactive OC fragments (Taylor et al. Metabolism 1988; 37:872-7.).
- the assay is said to be specific for the midmolecule epitope of hOC molecule according to information obtained from crossreactivity tests with tryptic fragments and synthetic peptide. The probable epitope for polyclonal antibody recognition is determined quite widely by the authors.
- the binding site of antisera is located in the midmolecule of the protein and probably involves amino acid 19 and at least a portion of the N-terminal sequence of the 20-43 tryptic digest fragment prior to amino acid 37.
- the assay is unable to distinquish decarboxylated hOC from carboxylated hOC in other words it is not dependent on the ⁇ -carboxylation degree of glutamic acids 17, 21 and 24 in hOC. Furthermore the detailed characterization of the fragments detected by the assay is missing. In addition, this assay is not suitable for routine measurement of urine because the desalting of urine samples before measurement is inevitable for the proper function of RIA.
- the concentration of serum osteocalcin is increased.
- the level of increase is partly dependent on the differences in the osteocalcin assays employed or the population studied, but is generally about 30 -50 % above the premenopausal values (Ravn et al. Bone 1996; 19:291-8, Bonde et al. J Clin Endocrinol Metab 1995; 80:864-8, Garnero et al. J Bone Miner Res 1996; 11:337-49, Akesson et al. J Bone Miner Res 1995; 1823-9).
- HRT hormon replacement therapy
- This invention relates to an isolated osteocalcin fragment derived from human urine, said fragment being characterized in that at least one of the glutamic acids in the position 17, 21 and 24 of the amino acid sequence
- the invention relates to a monoclonal antibody or recombinant antibody fragment having the capability of binding the human gamma- carboxylated osteocalcin fragment as defined above.
- the invention concerns a cell line producing said monoclonal antibody.
- the invention relates to an immunoassay for quantitative determination of a gamma-carboxylated osteocalcin fragment defined above, said immunoassay being characterized in that a sample containing said fragment is exposed to a monoclonal antibody or recombinant antibody fragment which binds said gamma-carboxylated osteocalcin fragment.
- the invention relates to a method for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders in an individual, said method being based on the quantitative determination of an osteocalcin fragment as defined above.
- Figure 1 A shows the nucleic acid and the a ino acid sequences of the synthetic human osteocalcin insert.
- Figure 1 B shows plasmid vector pGEX-3X (Pharmacia). The arrow indicates the Smal-ligation site of the hOC insert. The pfXa (protease factor Xa) cleavage site is located after the Ile-Glu-Gly-Arg -sequence.
- Figure 2 A shows SDS-PAGE and Figure 2 B shows Western blotting analysis of various osteocalcin forms.
- Lane 1. Low molecular weight (kDa) markers, lane 2.
- Affinity-purified GST (glutathione S-transferase), lane 3. hOC purified from human bone, lane 4.
- bOC bovine osteocalcin
- Affinity-purified GST-rhOC (GST- recombinant human osteocalcin fusion protein), lane 6.
- Chromatographically purified rhOC recombinant human osteocalcin i.e. the cleavage product from incubation of GST-rhOC with pfXa.
- Figure 3 is a schematic representation of the approximate epitopes recognized by the Mabs used in two-site hOC assays.
- the molecule has been divided into four epitope areas each of which is being recognized by different Mabs. Circled numbers indicate the number of the hOC specific immunoassay.
- Amino- and carboxyterminal amino acids have been marked as 1 and 49, respectively.
- the protease-sensitive sites have been indicated as R-R (arginine-arginine), the three Gla-residues are shown as well as the disulphide bridge (C-C).
- Figure 4 shows the determination of immunoreactive uhOC fragments in normal pubertal urine.
- Urine was subjected to immunoaffmity chromatography and solid phase extraction before HPLC fractionation. The fractions were measured for immunoreactive material with hOC specific assay #7. The squares refer to osteocalcin and the triangles to acetonitrile.
- Figures 5 A to 5 E show characteristics of the immunoreactive hOC fragments isolated from normal pubertal urine.
- Fig. 5 A Mass analysis of the most prominent fragment 44 isolated from urine spanning the amino acid residues 7-30 (Gly- Asp).
- Fig. 5 B Mass analysis of the urine hOC fragment 46 spanning the amino acid residues 6-30 (Leu- Asp).
- Fig. 5 C Mass analysis of the urine hOC fragment 43.
- Fig. 5 D Mass analysis of the urine hOC fragment 47.
- Fig. 5 E Characteristics of the hOC fragments isolated in urine and characteristics of intact hOC.
- Figure 6 shows the difference between the hOC concentrations in serum and urine between pubertal and adult samples as measured by the hOC IFMAs. hOC concentration in urine and serum samples was clearly higher in pubertal girls than in premenopausal women as measured with the hOC immunoassays.
- Figures 7 A and 7 B demonstrate hOC levels in pre-, postmenopausal and postmenopausal with HRT groups of women measured with the IFMAs.
- the concentrations have been obtained in serum (Fig. 7 A) and urine (Fig. 7 B) samples of adult females. In the urine samples the differences between menopausal groups were more obvious than in the serum samples even as measured with the same combination of Mabs.
- Figures 8 A to 8 D show correlations between different assays measured in urine and serum samples from adult female panel.
- Fig. 8 A Correlation between uhOC as measured by the assays #4 and #7.
- Fig. 8 B Correlation between uhOC as measured by the assays #7 and #9.
- Fig. 8 C Correlation between serum and urine samples as measured by the assay #7.
- Fig. 8 D Correlation between serum and urine samples as measured by the assay #4. DETAILED DESCRIPTION OF THE INVENTION
- the isolated osteocalcin fragment derived from human urine is a fragment spanning i) from the amino acid in position 7 to the amino acid in position 30, or ii) from the amino acid in position 6 to the amino acid in position 30 of the amino acid sequence
- the preferred monoclonal antibody or recombinant antibody fragment has a specificity to epitopes that have been identified on the gamma-carboxylated fragment of osteocalcin, wherein said fragment spans either i) from the amino acid in position 7 to the amino acid in position 30, or ii) from the amino acid in position 6 to the amino acid in position 30 of the amino acid sequence described above, and that all three glutamic acids in the positions 17, 21 and 24 of said sequence are gamma-carboxylated.
- the preferred immunoassay employs a monoclonal antibody or recombinant antibody fragment having the said specificity.
- the preferred immunoassay is a non-competitive immunoassay employing at least two different monoclonal antibodies or recombinant antibody fragments.
- the non-competitive immunoassay is preferably carried out in either a one-step or a two-step incubation procedure.
- Particularly preferable immunoassays are those where the two monoclonal antibodies employed are
- All the disclosed assays are highly sensitive and are based on widely characterized reagents. Difference in hOC concentration between the premenopausal and the pubertal group was clearly higher in urine samples than in serum samples. All the hOC assays discriminated the menopausal groups effectively using either serum or urine specimens. Due to their ability to detect different hOC forms, these assays should be of interest in monitoring various disease states, particularly of bone metabolism diseases. The assays are thus especially useful in methods for the measurement of the rate of bone turnover (formation and/or resorption) and/or for the investigation of metabolic bone disorders.
- L-broth culture medium contained 10 g/1 Bacto® Tryptone (Difco laboratories, Michigan, USA), 5 g/1 Bacto® Yeast extract (Difco) and 5 g/1 NaCl, pH 7.4. lsopropyl-1 -thio- ⁇ -D-galactoside, IPTG (Sigma Chemical CO, USA) was used for induction.
- PBS buffer consisted of 150 mM NaCl, 16 mM Na HP04, 4 mM NaH 2 PO/i, pH 7.3.
- PMSF and reduced glutathione were obtained from Sigma and protease factor Xa, pfXa from New England Biolabs.
- Glutathione Sepharose® 4B column (bed volume 8 ml) was obtained from Pharmacia.
- the size separation of the proteins was done with SDS-PAGE 25 % gradient Phastgel and using Low molecular weight markers for standardization (Pharmacia).
- Bovine osteocalcin (bOC) was obtained from Biodesign International, Kennebunkport, ME.
- a commercial anti-bOC Mab BD (Biodesign) was used as a primary antibody and a horseradish peroxidase linked anti-mouse immunoglobulin raised in sheep was used as a second antibody (Amersham, Buckinghamshire, England). ECL Western blotting reagents (Amersham) were used for visualization according to manufacturer's suggestions.
- PhastTransfer Semi-dry Transfer Kit (Pharmacia) according to PhastSystem manual.
- Synthetic human osteocalcin oligomers (Fig. 1A), each containing 88 nucleic acids (8 of them being complementary to each other) were hybridized at RT after phosphorylation of the ends.
- the single-stranded ends were filled by 1 U of Klenow polymerase and 100 ⁇ M of each deoxynucleotide (30 minutes incubation at 37 °C) to create a 160 base pair human osteocalcin insert, which contains a stop codon and a PstI restriction enzyme site at the 3' end of the gene (Fig. 1A).
- the blunt-ended insert was ligated in Smal-digested, dephosphorylated prokaryotic expression vector, pGEX-3X (Fig. IB).
- the recombinant plasmid was transformed into E.
- the sonicate was clarified by centrifugation (10,000g, 20 min, 4 °C) and filtered through a 0.45 ⁇ m filter before applying it to an equilibrated Glutathione Sepharose® 4B column according to manufacturer's suggestions.
- the eluate containing the GST-rhOC fusion protein was incubated with pfXa in 20 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl 2 , pH 8.0, using a protease to substrate ratio of 0.5 % (w/w) for 30 min at RT to release the rhOC portion (Nagai and Th ⁇ gersen Nature 1984; 309:810-2). Then rhOC was separated from the mixture reverse phase chromatography using a C8 RP-300 column. The optimization of the rhOC purification has been described in detail by Kak ⁇ nen et al. (1996).
- the expression vector contained the entire sequence of the hOC gene fused in frame to the 3' end of the Schistosoma japonicum glutathione S-transferase gene (Smith and Johnson Gene 1988;. 67:31-40) as verified by nucleic acid sequencing.
- the resulting fusion protein contains three additional amino acids between the protease factor Xa cleavage site and the first amino terminal tyrosine of the hOC gene (Fig. IB
- the molecular mass of the reverse phase HPLC purified rhOC was 6068.1 as determined by mass spectrometry.
- rhOC migrates similarly both to hOC purified from human femurs and bOC on SDS-PAGE (Fig. 2A, lanes 3, 4 and 6, respectively).
- Mab BD binds to hOC and bOC (Fig. 2B, lanes 3 and 4, respectively) and also to the both recombinant forms, GST-rhOC and rhOC (Fig. 2B, lanes 5 and 6, respectively).
- a 64 kDa band is also observed from the fusion protein sample (Fig. 2B, lane 5) which probably indicates a dimeric form of GST-rhOC.
- Mab BD does not bind to GST or to any of the molecular weight markers (Fig. 2B, lanes 1 and 2, respectively). 2. Production of the osteocalcin monoclonal antibodies
- Bovine osteocalcin was obtained from Biodesign International, Kennebunkport, ME.
- Freund's complete adjuvant Fca
- Freund's incomplete adjuvant Fa
- the Optimem-1 with glutamax-1, Dulbecco's Modified Eagle Medium (DMEM, 10 x liquid), L-glutamine, sodiumpyruvate (tissue culture tested), sodiumbicarbonate (tissue culture grade) and penicillin-streptomycin (P/S) solution were purchased from Gibco BRL, Life Technologies, Grand Island, NY, Hepes from Boehringer Mannheim, Germany and the fetal bovine serum from Hyclone, Logan, UT and were used as components in culture mediums. Reagents and equipment used for screening the hOC specific hybroma cell lines were obtained from Wallac Oy, Turku, Finland except the Europium-labeled hOC was prepared according to Hellman et al. (J Bone Miner Res 1996; 1 1 : 1165-75).
- Pristane (2,6, 10,14-tetramethyl pentadecan) used for the production of Mabs as ascitic fluid was obtained from Aldrich-Chemie, Steinhiem, Germany).
- Tecnomouse hollow-fiber bioreactor used for the large scale production of Mabs was obtained from Integra Biosciences AG, Wallisellen, Switzerland and Protein A agarose Affigel ® for the purification of the Mabs was from Bio-Rad, Richmond, CA.
- Bovine osteocalcin was coupled to keyhole limpet hemocyanin (KLH) as described (Young et al. Prostaglandines 1982; 23:603-13).
- KLH keyhole limpet hemocyanin
- Two three-month-old Balb/c male mice were i.p. immunized with 50 ⁇ g of bOC-KLH antigen mixed with Fca. The mice were boostered with the same amount of antigen in Fia. The final booster dose, 10 ⁇ g bOC-KLH in PBS, was given intravenously.
- splenocytes were fused to mouse myeloma cells SP 2/0 as described in more detail earlier (Lilja et al. Clin Chem 1991 ; 37: 1618-25).
- the hybridomas were grown in Optimem-1 with glutamax-1 containing 20 % of fetal bovine serum.
- the hOC specific Mabs were screened with immunofluorometric assay (IFMA) using rabbit antimouse Ig microtitration wells and hOC labeled with Europium as described earlier (Matikainen 1995).
- IFMA immunofluorometric assay
- the positive hybridomas were cloned at least twice by the limiting dilution method.
- Optimem-1 with glutamax-1 supplemented with 20 % of fetal bovine serum was used as culture medium.
- Cell lines 2H9F 1 1 F8 (2H9) and 6F9G4E10 (6F9) obtained from the GST-rhOC immunization and 3G8E1F11 (3G8), 1C4B 1D7E7 (1C4) and 3H8H2D2A12F12 (3H8) obtained from bOC immunizations were selected for further characterization.
- the Mabs were produced as ascites fluid in Balb/c mice primed with pristane and in Tecnomouse hollow-fiber bioreactor.
- DMEM (1 x solution) supplemented with L-glutamine, Hepes, sodiumpyruvate, sodiumbicarbonate and P/S was used as a culture medium in intracapillary circulation.
- Produced Mabs were purified by Protein A agarose chromatography using Affigel * purification kit according to manufacturer's suggestions.
- the streptavidin-coated microtiter plates were obtained from Wallac Oy and biotinylated rat antimouse Ig subclass specific Mabs from Serotec, Oxford, England.
- the synthetic osteocalcin peptide 7-19 containing Glu at residue 17 was purchased from Bachem, Switzerland and bovine osteocalcin (bOC) was obtained from Biodesign International, Kennebunkport, ME.
- Osteocalcin from human femurs was purified by modifying a previously described method (Gundberg et al. Meth Enzymol 1984; 107:516-544) as explained in detail by Hellman et al. (1996).
- Mabs were characterized for their binding to Eu-labeled intact hOC, bOC and tryptic or synthetic peptides as described (Hellman et al. 1996).
- the antibodies 1 C4 and 3H8 obtained by immunization with bOC conjugated to KLH recognized the tryptic 20-43 fragment.
- labeling of intact bOC and hOC abolished their immunoreactivity with 3G8, suggesting either that intact Tyr (1) is needed for efficient binding of that the Eu-chelate causes steric hindrance.
- Hybridoma Immunoglobulin Eu-labeled OC forms recognized one Immunogen class H-chain " Eu-hOC Eu hOC l-19 Eu-hOC 7-19 Ku-hOC 15-31 Eu-hOC 2 Q- 3 Eu-bOC
- the Mabs 3G8, 2H9 and 6F9 were biotinylated with BITC and the Mabs 2H9, 6F9, 1C4 and 3H8 were labeled with europium(III) chelate in reaction conditions previously described (Hellman et al, 1996).
- the two-site immunoassay utilized time-resolved fluorometry using lanthanide chelate labels, like europium, as a detection system (Soini and Lovgren CRC Crit Rev Anal Chem. 1987; 18: 105-53).
- the assays # 4 (bio-2H9/Eu-6F9), #7 (bio-6F9/Eu-lC4) and #9 (bio- 6F9/Eu-3H8) were able to detect the full length hOC and also the large NH 2 - terminal fragment.
- Assay #4 measured both ⁇ -carboxylated and fully decarboxylated form of hOC.
- the #9 and #7 assays distinctively preferred the carboxylated form of hOC. Determination of the affinity constants of labeled Mabs were done according to Hellman et al. 1996 using Scatchard analysis (Scatchard, Ann NY Acad Sci 1949; 51 :660-72). Characteristics of the assays are summarized in Table 2.
- the hOC specific antibodies could be utilized in competitive assays as a capture antibody.
- hOC fragments in urine compete with the Eu-labeled hOC for binding to the limited number of capture Mabs.
- Mabs 2H9, 1 C4 and 3H8 also Eu-labeled bOC could be used due to crossreactivities explained in Table 1.
- hOC and CPYhOC Carboxy-peptidase Y digested hOC
- DTPA diethylenetriaminepentaaceticacid
- TSA-buffer 50 mM Tris-HCl, 150 mM NaCl, 15 mM NaN 3 , pH 7.75
- Materials and equipment used in the OC IFMAs have been listed in the section 3.
- the plates were shaken for 2 h at RT followed by washing six times with Delfia ® Wash Solution. To detect the Eu fluorescence, 200 ⁇ l of Delfia ® Enhancement solution per well was added. Prior to the measurement with the Delfia ® Research Fluorometer the plates were shaken 30 min at RT.
- the lower limit of the detection of the different assays were determined based on two standard deviations of the background signal produced by the standard diluent and was under 0.1 ⁇ g/L for each assay.
- the developed IFMAs showed a linear response of over four orders of magnitude and were highly reproducible.
- the calibration curve for assay #4 was prepared using purified hOC purified hOC in 7.5 % (w/v) DTPA-treated BSA in TSA buffer as a standard covering the range from 0.05 to 16 ng/ml.
- Carboxy-peptidase Y digested hOC (CPY hOC) in the same diluent covering the range from 0.05 to 16 ng/ml was used for standardization for the assays #7 and #9.
- Carboxy-peptidase Y digested hOC (CPY hOC) used for standardization of the urine IFMAs was produced as explained in section 3. Immuno affinity chromatography coupled with purified 6F9Mab (section 2) using Affi-Gel Hz Ixnmunoaffinity kit from Bio-Rad, a C-18 solid phase extraction cartridge (Millipore) and a C-4 reverse phase HPLC column (Vydac, Hesperia, CA, U.S.A.) were used for the isolation of uhOC fragments.
- Matrix assisted laser deso ⁇ tion MALDI-TOF mass spectrometer (LASERMAT R , Thermo Bioanalysis Ltd., U.K.) was employed for mass determinations and a protein sequencer (Applied Biosystems model All A) equipped with an on-line Applied Biosystems model 120A PTH amino acid analyzer was used for the NH 2 -terminal amino acid sequence analyses.
- Urine pool was collected in the morning from one healthy male volunteer aged 13 years and stored at +4 °C. Within three hours the pool was aliquoted and frozen at - 70 °C. Later it was stored at -20 °C. Urine pool was thawed, centrifuged and filtrated before subjected to any isolation steps.
- Immunoreactive uhOC in both urine pool and different steps of isolation process was measured with a two-site immunoassay recognizing, not only the intact hOC, but also the N-terminal mid-fragment of hOC (amino acid residues 1 - 43) (Fig. 3).
- the assay used monoclonal antibodies (Mabs) 6F9 and 1 C4 as a capture and tracer Mab, respectively (combination #7).
- the calibration curve was prepared using carboxy-peptidase Y digested hOC (CPY hOC) as a standard.
- the amount of immunoreactive uhOC in puberty urine pool was 100 ng/ml.
- the assays #9 (Mab combination 6F9/3H8) and #4 (Mab combination 2H9/6F9) were utilized to determine the immunoreactive fragments as described in section 4.
- the sample containing the immunoreactive fragments was applied onto a Vydac C-4 (2.1 mm x 150 mm) reverse phase HPLC column, eluted with an acetonitrile gradient (Fig. 4) and the peak fractions detected at 276 nm were collected manually.
- the sample contained multiple immunoreactive fragments of OC, which eluted between 70 min (35% AcN), and 82 min (48% AcN) (Fig.4).
- Fractions containing 1.4 - 19.5 ⁇ g/ml of immunoreactive uhOC were subjected to further analysis. Characterization of osteocalcin fragments
- HPLC fractions were analyzed by the two-site immunoassays #7, #9 and #4 as before and fractions containing immunoreactive uhOC fragments were subjected to MALD1-TOF mass spectrometry and N-terminal amino acid sequencing.
- the molecular masses of the prominent ions in mass spectrometry were 2778, 2814, 2930 and 3005.
- the sequence obtained from fraction 44 matches with hOC starting from residue Gly(7). Taking into account the experimental mass 2814, the fragment spans residues 7-30, with ⁇ -carboxylated residues at positions 17, 21 and 24 giving a calculated mass of 2812 (Fig.
- ⁇ - carboxylation of the Glu residues is further supported by the fact that ⁇ -carboxylated Glu residues are known not to give signal using the sequencing technique in question (Caims et al. (1991) Anal Biochem. 199, 93-97).
- Fraction 46 was subjected to trypsin digestion to demonstrate that the fragment can be cleaved as expected (after Arg residue).
- the determined N-terminal sequence matches with hOC starting from residue Leu(6).
- the determined mass of the N- terminal part of the fragment cleaved with trypsin was 1566 and in accordance with the expected mass mass (1565 with ⁇ -carboxylated Glu 17).
- the fragment spans residues 6-30 of hOC with three ⁇ -carboxylated residues as above (calculated mass 2925).
- the ion species with masses 2778 (Fig. 5 C) and 3005 (Fig. 5 D) represent close structural variants of the same hOC region, based on immunoreactivity, cliromatographic behaviour and molecular mass. Such structural variability can be caused by partial lack of ⁇ -carboxylation or additional 1 -2 residues, and/or combinations of both.
- the characteristics of the fragments have been described in figure 5 E.
- immunoassay #1 also assay #9 recognize effectively these forms of urine osteocalcin.
- Epitope of #4 differs slightly from epitope recognized by the combination #7 and #9 because the combination could not recognize the 7-30 fragment but could detect the fragment which mass was 3005.
- Urine may contain shorter hOC fragments which remain to be characterized.
- FSH concentration of serum samples was measured by Delfia ® hFSH assay (Wallac, Turku, Finland).
- the creatinine concentration in urine samples was measured using AU OLYMPUS 510 equipment according to manufacturer's protocols. The protocols of the shOC and uhOC assays have been described in section 5.
- Serum samples were measured with intact hOC assay specific for full-length hOC (#2), with total hOC assay recognizing not only the intact hOC, but also the N- terminal midfragment of hOC (#4) and with two assays dependent on the degree of ⁇ -carboxylation of the glutamic acids in hOC (#7 and #9).
- the urine samples were measured with two ⁇ -carboxylation dependent assay (#7 and #9) and also with assay #4.
- the urine osteocalcin values used for analysis have been corrected for creatinine.
- Table 4 Percentual differences and statistical significancies between menopausal groups as measured by hOC IFMAs in serum and urine samples.
- the assays definitely detected different forms of circulating hOC, their performance in measuring the serum panel was almost identical.
- the IFMAs were even more effective in discriminating postmenopausal group from premenopausal group and also postmenopausal group under HRT from postmenopausal control group when measured in urine samples.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI973371A FI973371A0 (fi) | 1997-08-15 | 1997-08-15 | Nya isolerade peptider |
FI973371 | 1997-08-15 | ||
PCT/FI1998/000550 WO1999009058A1 (en) | 1997-08-15 | 1998-06-24 | Isolated osteocalcin fragments |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1003778A1 true EP1003778A1 (en) | 2000-05-31 |
Family
ID=8549365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98929457A Withdrawn EP1003778A1 (en) | 1997-08-15 | 1998-06-24 | Isolated osteocalcin fragments |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1003778A1 (it) |
JP (1) | JP2001514875A (it) |
FI (1) | FI973371A0 (it) |
WO (1) | WO1999009058A1 (it) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI990693A0 (fi) * | 1999-03-29 | 1999-03-29 | Kaekoenen Sanna Maria | Menetelmä luunmurtumien ennustamiseksi osteokalsiinimääritysten avulla |
WO2001013123A2 (de) * | 1999-08-14 | 2001-02-22 | november Aktiengesellschaft Gesellschaft für Molekulare Medizin | Verfahren zur indirekten bestimmung des blutgerinnungsstatus |
SE0000675D0 (sv) | 2000-03-02 | 2000-03-02 | Protease Ab | Monoclonal antibodies |
GB0107393D0 (en) * | 2001-03-23 | 2001-05-16 | Osteometer Biotech As | A method of assaying osteocalcin fragments in body fluids a test kit and means for carrying out the method and use of the method to monitor bone resorption |
WO2019211866A1 (en) * | 2018-04-30 | 2019-11-07 | National Institute Of Immunology | Carboxylated osteocalcin for treatment of amyloidosis or diseases associated with abnormal protein folding |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE152525T1 (de) * | 1992-02-27 | 1997-05-15 | Delmas Pierre Dr | Einschätzung der beinzerbrechlichkeit und voraussage osteoporotischer bruchaussicht unter verwendung einer quantitativen bestimmung zirkulierendes unterkarboxyliertes osteokalzin |
JP3894381B2 (ja) * | 1996-04-10 | 2007-03-22 | 株式会社ペプチド研究所 | 抗Glu▲17▼−オステオカルシン抗体 |
-
1997
- 1997-08-15 FI FI973371A patent/FI973371A0/fi not_active Application Discontinuation
-
1998
- 1998-06-24 JP JP2000509736A patent/JP2001514875A/ja active Pending
- 1998-06-24 WO PCT/FI1998/000550 patent/WO1999009058A1/en active Application Filing
- 1998-06-24 EP EP98929457A patent/EP1003778A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9909058A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2001514875A (ja) | 2001-09-18 |
FI973371A0 (fi) | 1997-08-15 |
WO1999009058A1 (en) | 1999-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Curtiss et al. | A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins. | |
US7264938B2 (en) | Method of detecting native proBNP | |
US8470543B2 (en) | Methods for differentiating and monitoring parathyroid and bone status related diseases | |
CA2359667C (en) | Method of identifying n-terminal probnp | |
US7670805B2 (en) | Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 | |
US20060286107A1 (en) | Parathyroid hormone antibodies and related methods | |
EP1365022A1 (en) | Adiponectin-associated protein | |
US6248869B1 (en) | Troponin I forms and use of the same | |
JP6178343B2 (ja) | 酸化的ストレスに苦しむ患者の上皮小体ホルモンを測定する手段および方法 | |
Biral et al. | Myosin subunit composition in human developing muscle | |
Ivaska et al. | Identification of novel proteolytic forms of osteocalcin in human urine | |
EP1003778A1 (en) | Isolated osteocalcin fragments | |
US20040259167A1 (en) | Isolated osteocalcin fragments | |
EP1766411B1 (en) | Method for determining a tissue degradation process by detection of comp neoepitopes | |
US5753522A (en) | Purified protein for identifying a cancer-associated retinopathy autoantibody | |
JP3894381B2 (ja) | 抗Glu▲17▼−オステオカルシン抗体 | |
Matikainen et al. | Demonstration of the Predominant Urine Osteocalcin Fragments Detectable by Two‐Site Immunoassays | |
KR100460292B1 (ko) | 체액중의단백질파편검정 | |
EP0410066A1 (en) | Improvements in or relating to organic compounds | |
WO2002077639A2 (en) | Osteocalcin fragments assay to monitor bone resorption | |
US8012694B2 (en) | Assay for the detection of phosphorylated PTH | |
JP2007045834A (ja) | 抗Glu17−オステオカルシン抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19991231 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE ES FR GB IT |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080826 |